09
Mar
2010
Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Coagulation, X - Inflammation, XX - MA
Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!
08
Mar
2010
Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Bioenergetics), XX - MA
Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science [...]
03
Mar
2010
Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Device (Delivery), X - Device (Diabetes), X - Device (Osteoporosis), XX - MA
MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.
25
Feb
2010
23
Feb
2010
Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - CF, X - Pancreas, XX - MA
Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.
23
Feb
2010
18
Feb
2010
11
Feb
2010
05
Feb
2010
Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Biomarker, X - Device (Diagnostic), XX - MA
On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.
Note: [...]
05
Feb
2010
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]